Welcome to our dedicated page for Cresco Labs news (Ticker: CRLBF), a resource for investors and traders seeking the latest updates and insights on Cresco Labs stock.
Cresco Labs Inc. reports developments in branded cannabis products, retail dispensaries, cultivation, production and state-regulated market access. The company operates Sunnyside dispensaries and distributes cannabis brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s and Remedi.
Recurring updates cover quarterly financial results, dispensary openings, medical and adult-use market activity, cannabis licensing matters and operational growth initiatives. Company communications also address branded product distribution, retail execution, balance sheet and cash-flow themes, community outreach, workforce development and legislative or regulatory engagement in the cannabis industry.
Cresco Labs (CSE:CL, OTCQX:CRLBF), a leading U.S. cannabis wholesaler, will announce its Q2 2022 financial results on August 17, 2022, before market opening. The company plans to hold a conference call at 8:30 AM EST to discuss the results and key business highlights. After the event, an archive of the webcast will be available for one year on the Cresco Labs investor relations website. Cresco Labs aims to normalize the cannabis industry while operating the largest social equity and educational initiative in the sector.
Cresco Labs (CSE:CL, OTCQX:CRLBF) held its annual shareholder meeting on July 15, 2022, where shareholders approved the election of 11 directors, including Charles Bachtell and Robert M. Sampson. Marcum LLP was reappointed as auditor. A significant resolution was passed regarding the company's Super Voting Shares, amending the investment agreement to facilitate a share repurchase for $800,001 after a future U.S. listing event. This decision prevents the issuance of new Super Voting Shares and mandates cancellation upon repurchase.
Columbia Care Inc. (CCHWF) has received final approval from the Supreme Court of British Columbia for its acquisition by Cresco Labs (CRLBF). This follows overwhelming shareholder support during a meeting on July 8, 2022. The CEO, Nicholas Vita, emphasized the milestone in achieving a leading position in the cannabis industry. The arrangement includes a divestiture process in key states, progressing well with strong demand from bidders. The divestitures are expected to align with the Arrangement's closing anticipated at the end of 2022.
Columbia Care (OTCQX: CCHWF) announced overwhelming shareholder support for its business combination with Cresco Labs (OTCQX: CRLBF), with 98.5% voting in favor at a special meeting held on July 8, 2022. The arrangement will see Cresco Labs acquire all issued shares of Columbia Care. A total of 169,938,646 shares were represented in the voting, constituting 42.6% of the outstanding shares. CEO Nicholas Vita expressed gratitude for the support as the company anticipates the transaction's completion by year-end.
Cresco Labs (OTCQX:CRLBF), a leading U.S. wholesaler of branded cannabis products, announced participation in key industry conferences in June 2022. Chief Commercial Officer Greg Butler will speak at the Jefferies Cannabis Summit on June 2 and CEO Charles Bachtell will engage in a fireside chat at the Oppenheimer Consumer Growth and E-Commerce Conference on June 14. Cresco is committed to normalizing the cannabis industry and operates the largest Social Equity and Educational Development initiative, SEED.
Cresco Labs reports a robust 20% year-over-year revenue growth for Q1 2022, reaching $214 million. The company also achieved a 45% increase in adjusted EBITDA, totaling $51 million. Their gross profit was $113 million (53% margin), up 29% year-over-year. Retail sales surged 44% to $119 million, averaging $2.5 million per store. Cresco maintains its market leadership in branded cannabis, despite a challenging environment. They passed the HSR review for the Columbia Care acquisition, marking a significant milestone.
Cresco Labs has announced the expiration of the 30-day waiting period under the HSR Act, a significant milestone in its acquisition of Columbia Care. CEO Charles Bachtell emphasized the benefits of leveraging Cresco's leading cannabis portfolio across a wider market, particularly in the ten states projected for substantial revenue growth by 2025. The transaction, initially detailed in March 2022, is still subject to shareholder approval and other regulatory conditions, with both companies aiming for a year-end closing. Cresco Labs ranks as the largest wholesaler of branded cannabis products in the U.S.
Cresco Labs (CSE:CL, OTCQX:CRLBF), a leading U.S. cannabis wholesaler, will release its Q1 2022 financial results on May 18, 2022, before market opening. A conference call is scheduled for 8:30 am EDT on the same day to discuss the results and key business highlights. Cresco Labs operates with a mission to professionalize the cannabis industry, offering a wide range of trusted brands. It emphasizes consumer engagement through its Sunnyside dispensaries and supports industry education through its SEED initiative.
Cresco Labs (OTCQX:CRLBF), a leading U.S. cannabis wholesaler, announced its participation in the Canaccord Genuity Virtual Cannabis Conference on May 11, 2022. CEO Charles Bachtell will engage in a fireside chat with analyst Derek Dley, alongside one-on-one investor meetings. Cresco Labs, recognized for its consumer-focused brands such as Sunnyside and High Supply, aims to normalize the cannabis industry and actively promotes social equity through its SEED initiative.
Cresco Labs introduced its premium craft cannabis brand, FloraCal Farms, featuring unique genetics through curated flower, live rosin vapes, and concentrates.
This new line is available at all Illinois Sunnyside stores ahead of the popular 420 holiday. FloraCal Farms aims to cater to sophisticated consumers with artisanal craftsmanship and innovative solventless extraction methods.
CEO Charles Bachtell announced plans for further market expansion and diverse pricing strategies to enhance competitiveness.